Breast Cancer Research and Treatment

, Volume 107, Issue 1, pp 119–122

BARD1 and breast cancer in Poland

Authors

    • International Hereditary Cancer Center, Department of Genetics and PathologyPomeranian Medical University
  • Cezary Cybulski
    • International Hereditary Cancer Center, Department of Genetics and PathologyPomeranian Medical University
  • Anna Szymańska
    • International Hereditary Cancer Center, Department of Genetics and PathologyPomeranian Medical University
  • Tomasz Huzarski
    • International Hereditary Cancer Center, Department of Genetics and PathologyPomeranian Medical University
  • Tomasz Byrski
    • International Hereditary Cancer Center, Department of Genetics and PathologyPomeranian Medical University
  • Jacek Gronwald
    • International Hereditary Cancer Center, Department of Genetics and PathologyPomeranian Medical University
  • Tadeusz Dębniak
    • International Hereditary Cancer Center, Department of Genetics and PathologyPomeranian Medical University
  • Bohdan Górski
    • International Hereditary Cancer Center, Department of Genetics and PathologyPomeranian Medical University
  • Elżbieta Kowalska
    • International Hereditary Cancer Center, Department of Genetics and PathologyPomeranian Medical University
  • Steven A. Narod
    • Centre for Research on Women’s Health
  • Jan Lubiński
    • International Hereditary Cancer Center, Department of Genetics and PathologyPomeranian Medical University
Epidemiology

DOI: 10.1007/s10549-007-9537-4

Cite this article as:
Jakubowska, A., Cybulski, C., Szymańska, A. et al. Breast Cancer Res Treat (2008) 107: 119. doi:10.1007/s10549-007-9537-4
  • 91 Views

Abstract

Purpose

To investigate whether or not a genetic variant in BARD1 (Cys557Ser) contributes to early-onset breast cancer in Poland, or modifies the risk of breast cancer in women with an inherited predisposition to breast cancer.

Experimental design

We studied 3,188 unselected Polish women with breast cancer and 1,038 healthy controls. All women were genotyped for the BARD1 Cys557Ser variant and for known founder mutations in BRCA1 (three mutations), CHEK2 (four mutations), and NBS1 (one mutation).

Results

A BARD1 variant was seen in 150 of 3,188 breast cancer cases (4.7%) and in 40 of 1,038 controls (3.8%) (OR = 1.2; 95% CI = 0.9–1.7). The risk associated with the BARD1 variant was not significantly greater in women with familial cancer (OR = 1.5; 95% CI = 0.8–2.7), or with an inherited mutation in BRCA1 (OR = 0.9; 95% CI = 0.4–2.2), CHEK2 (OR = 1.0; 95% CI = 0.5–2.1), or NBS1 (OR = 1.3; 95% CI = 0.2–10.2). Modest associations were observed among the subgroups of women with very early onset breast cancer (OR = 2.9; 95% CI = 1.2–7.1) and with medullary breast cancer (OR = 1.8; 95% CI = 0.9–3.7).

Conclusion

There was no clear association between the presence of the BARD1 Cys557Ser allele and breast cancer in Poland. Furthermore, the BARD1 Cys557Ser allele does not appear to modify the risk of breast cancers among carriers of BRCA1 mutations, or of other predisposing mutations. The allele may predispose to breast cancers of certain histologic subtypes, but further studies are needed to confirm these findings.

Keywords

BARD1BRCA1Breast cancerCHEK2NBS1

Copyright information

© Springer Science+Business Media, LLC 2007